Regeneron Pharmaceuticals (NASDAQ: REGN): The stock not only generated 248% return in the past 52 weeks, but it also has healthy cash balance to help its future course of action. Regeneron Pharmaceuticals consistently increased throughout the year and it oscillated in the range of $50.27 and $188.95. The company started the year by settling a patent litigation with Genentech for US sales of EYLEA injection. Later in the year, it received FDA and EU approval for its colorectal cancer therapy Zeltrap. Regeneron Pharmaceuticals will collaborate with Bayer Healthcare to market this new treatment in various markets. Its stock trades at a P/E ratio of 93.59, which makes it more expensive than many of its peers, but given the strong potential for its therapies, Regeneron Pharmaceuticals is likely to perform well in the coming year as well and should be a strong contender for inclusion into your portfolio.